Opko Health Inc. (NYSE:OPK) CEO Phillip Md Et Al Frost purchased 5,400 shares of the business’s stock in a transaction on Wednesday, November 9th. The shares were acquired at an average price of $9.33 per share, with a total value of $50,382.00. Following the completion of the transaction, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at $28,633,312.83. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Tuesday, November 8th, Phillip Md Et Al Frost bought 23,100 shares of Opko Health stock. The shares were purchased at an average price of $9.22 per share, with a total value of $212,982.00.
  • On Wednesday, November 2nd, Phillip Md Et Al Frost bought 10,000 shares of Opko Health stock. The shares were purchased at an average price of $9.48 per share, with a total value of $94,800.00.
  • On Tuesday, November 1st, Phillip Md Et Al Frost bought 10,000 shares of Opko Health stock. The shares were purchased at an average price of $9.49 per share, with a total value of $94,900.00.
  • On Monday, October 31st, Phillip Md Et Al Frost bought 11,800 shares of Opko Health stock. The shares were purchased at an average price of $9.43 per share, with a total value of $111,274.00.
  • On Friday, October 28th, Phillip Md Et Al Frost bought 10,000 shares of Opko Health stock. The shares were purchased at an average price of $9.46 per share, with a total value of $94,600.00.
  • On Thursday, October 27th, Phillip Md Et Al Frost bought 10,000 shares of Opko Health stock. The shares were purchased at an average price of $9.36 per share, with a total value of $93,600.00.
  • On Wednesday, October 26th, Phillip Md Et Al Frost bought 5,600 shares of Opko Health stock. The shares were purchased at an average price of $9.27 per share, with a total value of $51,912.00.
  • On Tuesday, October 25th, Phillip Md Et Al Frost bought 3,600 shares of Opko Health stock. The shares were purchased at an average price of $9.38 per share, with a total value of $33,768.00.
  • On Monday, October 24th, Phillip Md Et Al Frost bought 1,800 shares of Opko Health stock. The shares were purchased at an average price of $9.50 per share, with a total value of $17,100.00.
  • On Friday, October 21st, Phillip Md Et Al Frost bought 1,800 shares of Opko Health stock. The shares were purchased at an average price of $9.38 per share, with a total value of $16,884.00.

Shares of Opko Health Inc. (NYSE:OPK) traded down 0.31% during trading on Thursday, hitting $9.55. 775,293 shares of the company’s stock were exchanged. The firm has a 50-day moving average price of $9.93 and a 200-day moving average price of $9.89. Opko Health Inc. has a one year low of $7.12 and a one year high of $11.85. The stock has a market cap of $5.26 billion and a P/E ratio of 39.96.

Opko Health (NYSE:OPK) last issued its quarterly earnings results on Monday, November 7th. The company reported ($0.03) EPS for the quarter, meeting the consensus estimate of ($0.03). The firm had revenue of $298 million for the quarter, compared to the consensus estimate of $322 million. The business’s revenue for the quarter was up 108.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.25 earnings per share. Equities research analysts expect that Opko Health Inc. will post ($0.06) EPS for the current fiscal year.

Insider Buying and Selling by Quarter for Opko Health (NYSE:OPK)

OPK has been the subject of several research analyst reports. JPMorgan Chase & Co. set a $14.00 price objective on shares of Opko Health and gave the stock a “buy” rating in a report on Tuesday, August 9th. Zacks Investment Research upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a report on Tuesday, October 25th. Oppenheimer Holdings Inc. restated a “hold” rating on shares of Opko Health in a report on Monday, October 10th. Finally, Jefferies Group restated a “hold” rating and issued a $10.00 price objective on shares of Opko Health in a report on Monday, October 10th. Five research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Opko Health currently has a consensus rating of “Buy” and an average target price of $13.20.

A number of institutional investors have recently modified their holdings of the stock. Northern Trust Corp increased its position in shares of Opko Health by 7.1% in the third quarter. Northern Trust Corp now owns 1,410,451 shares of the company’s stock valued at $14,937,000 after buying an additional 94,071 shares during the last quarter. Shufro Rose & Co. LLC increased its position in shares of Opko Health by 18.7% in the third quarter. Shufro Rose & Co. LLC now owns 176,500 shares of the company’s stock valued at $1,869,000 after buying an additional 27,800 shares during the last quarter. Suntrust Banks Inc. increased its position in shares of Opko Health by 4.3% in the third quarter. Suntrust Banks Inc. now owns 12,059 shares of the company’s stock valued at $126,000 after buying an additional 500 shares during the last quarter. American Asset Management Inc. purchased a new position in shares of Opko Health during the third quarter valued at approximately $326,000. Finally, Emerald Acquisition Ltd. increased its position in shares of Opko Health by 35.4% in the third quarter. Emerald Acquisition Ltd. now owns 65,945 shares of the company’s stock valued at $699,000 after buying an additional 17,250 shares during the last quarter.

Opko Health Company Profile

OPKO Health, Inc (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations.

5 Day Chart for NYSE:OPK

Receive News & Stock Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related stocks with our FREE daily email newsletter.